X0306 4 2018-11-16 0 0001175680 CytoDyn Inc. CYDY 0001532878 Pourhassan Nader 1111 MAIN STREET, SUITE 660 VANCOUVER WA 98660 1 1 0 0 President and CEO Common Stock 2018-11-16 4 A 0 161489 A 161489 D Common Stock 2018-11-16 4 A 0 15750 A 15750 I By Spouse Stock Options (right to buy) 0.64 2018-11-16 4 A 0 200000 A 2018-05-29 2019-05-29 Common Stock 200000 200000 D Stock Options (right to buy) 2.00 2018-11-16 4 A 0 500000 A 2015-07-31 2021-07-31 Common Stock 500000 500000 D Stock Options (right to buy) 2.75 2018-11-16 4 A 0 54545 A 2012-03-23 2022-03-23 Common Stock 54545 54545 D Stock Options (right to buy) 0.90 2018-11-16 4 A 0 200000 A 2018-06-30 2025-06-30 Common Stock 200000 200000 D Stock Options (right to buy) 0.87 2018-11-16 4 A 0 650000 A 2025-11-23 Common Stock 650000 650000 D Stock Options (right to buy) 0.75 2018-11-16 4 A 0 304000 A 2026-01-04 Common Stock 304000 304000 D Stock Options (right to buy) 1.09 2018-11-16 4 A 0 600000 A 2026-06-01 Common Stock 600000 600000 D Stock Options (right to buy) 0.57 2018-11-16 4 A 0 300000 A 2027-06-01 Common Stock 300000 300000 D Stock Options (right to buy) 0.80 2018-11-16 4 A 0 600000 A 2017-05-31 2023-02-15 Common Stock 600000 600000 D Stock Options (right to buy) 0.49 2018-11-16 4 A 0 350000 A 2028-06-08 Common Stock 350000 350000 D Stock Options (right to buy) 0.565 2018-11-16 4 A 0 1000000 A 2028-11-08 Common Stock 1000000 1000000 D On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). The options (including predecessor options) vest upon the achievement of certain strategic milestones specified in the award agreement. The options (including predecessor options) vest in three equal annual installments commencing on June 1, 2017. The options (including predecessor options) vest in three equal annual installments commencing on June 1, 2018. The options vest in three equal annual installments commencing on June 1, 2019. 50% of the options were fully vested and exercisable as of their issuance date, and 50% of the options vest on April 8, 2019. /s/ Michael D. Mulholland, as attorney-in-fact 2018-11-16